Skip to main content

Marker Therapeutics, Inc 10-Q for FY2026 Q3

Marker Therapeutics, Inc. (MRKR)

10-Q 2026-11-16 For: 2026-09-30
View Original
Added on November 17, 2026

About this 10-Q

Marker Therapeutics, Inc filed this 10-Q on November 16, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Marker Therapeutics' nine-month net loss narrowed to $6.8 million from $10.5 million, as research and development expenses fell 33%. The company cites substantial doubt about going concern and anticipates funding operations into the second quarter of 2027. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$1.84M
compared with a net loss of $2M a year earlier
Diluted EPS
-$0.10
compared with -$0.12 a year earlier